+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Low-dose fluvastatin reverses the hypoxic pulmonary adventitial fibroblast phenotype in experimental pulmonary hypertension



Low-dose fluvastatin reverses the hypoxic pulmonary adventitial fibroblast phenotype in experimental pulmonary hypertension



American Journal of Respiratory Cell and Molecular Biology 47(2): 140-148



Hypoxic pulmonary hypertension is a worldwide public health problem. Statins attenuate hypoxic pulmonary hypertension in animal models, but the mechanism of action and applicability of these results to human treatment are not established. In hypoxic models, pulmonary artery fibroblast proliferation contributes substantially to pulmonary vascular remodeling. We previously showed that acute hypoxic pulmonary adventitial fibroblast proliferation can be selectively inhibited by statins and p38 mitogen-activated protein (MAP) kinase inhibitors. Here we used complementary chronic hypoxic and acute hypoxic coculture models to obtain necessary preclinical information regarding the utility of fluvastatin in the treatment of chronic hypoxic pulmonary hypertension. The effects of fluvastatin, cholesterol pathway intermediates, and related inhibitors on hypoxic adventitial fibroblast proliferation, p38 MAP kinase phosphorylation, and pulmonary artery smooth muscle cell proliferation were determined, using complementary chronic hypoxic rat and acute hypoxic bovine cell models. Fluvastatin reversed the proliferative phenotypic switch in adventitial fibroblasts from chronic hypoxic animals. This effect was circulation-specific, and implicated a Rac1-p38 MAP kinase signaling pathway. Coculture and conditioned media experiments also implicated this statin-sensitive signaling pathway in the release of pulmonary artery smooth muscle cell mitogens by hypoxic pulmonary adventitial fibroblasts. Treprostinil, sildenafil, and bosentan exerted no effect on the hypoxic fibroblast phenotype. Phenotypic changes (increased proliferation and mitogen release) in pulmonary artery fibroblasts during chronic hypoxia are dependent on a Rac1-p38 MAP kinase signaling pathway. The inhibition of these phenotypic changes with fluvastatin may be therapeutically relevant in high-altitude residents and in patients with hypoxic lung disease.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 036527109

Download citation: RISBibTeXText

PMID: 22383583

DOI: 10.1165/rcmb.2011-0411OC


Related references

miR-29a-3p attenuates hypoxic pulmonary hypertension by inhibiting pulmonary adventitial fibroblast activation. Hypertension 65(2): 414-420, 2015

Osteopontin is an endogenous modulator of the constitutively activated phenotype of pulmonary adventitial fibroblasts in hypoxic pulmonary hypertension. American Journal of Physiology. Lung Cellular and Molecular Physiology 303(1): L1-L11, 2012

Alterations in pulmonary artery adventitial cell matrix protein gene expression in hypoxic pulmonary hypertension. American Review of Respiratory Disease 145(4 PART 2): A482, 1992

MicroRNAs and PARP: co-conspirators with ROS in pulmonary hypertension. Focus on "miR-223 reverses experimental pulmonary arterial hypertension". American Journal of Physiology. Cell Physiology 309(6): C361-C362, 2015

Regulation of adventitial fibroblast functions in pulmonary hypertension. Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica 152(5): 258, 2018

Developmental and hypoxic regulation of pulmonary artery adventitial fibroblast insulin-like growth factor binding proteins. Pediatric Research 37(4 PART 2): 71A, 1994

Adventitial Fibroblast Nox4 Expression and ROS Signaling in Pulmonary Arterial Hypertension. Advances in Experimental Medicine and Biology 967: 1-11, 2018

Chronic obstructive pulmonary disease phenotype desaturator with hypoxic vascular remodelling and pulmonary hypertension obtained by cluster analysis. Multidisciplinary Respiratory Medicine 7(1): 39, 2012

A novel Ca+ channel antagonist reverses cardiac hypertrophy and pulmonary arteriolar remodeling in experimental pulmonary hypertension. European Journal of Pharmacology 702(1): 316-322, 2013

A novel Ca2+ channel antagonist reverses cardiac hypertrophy and pulmonary arteriolar remodeling in experimental pulmonary hypertension. European Journal of Pharmacology 702(1-3): 316-322, 2014

Dichloroacetate reverses chronic hypoxic pulmonary hypertension. Circulation 102(18 Supplement): II 100, October 31, 2000

Adenosine triphosphate (ATP) treatment of hypoxic pulmonary hypertension (HPH): comparison of dose dependence in pulmonary and renal circulations. Journal of Surgical Research 46(4): 374-379, 1989

Circulating mononuclear cells with a dual, macrophage-fibroblast phenotype contribute robustly to hypoxia-induced pulmonary adventitial remodeling. Chest 128(6 Suppl): 583s-584s, 2005

Inhibition of Src activation reverses pulmonary vascular remodeling in experimental pulmonary arterial hypertension via Akt/mTOR/HIF-1<alpha> signaling pathway. Experimental Cell Research 2019, 2019

Serotonin receptors take the TRiPV4 highway in chronic hypoxic pulmonary hypertension. Focus on "TRPV4 channel contributes to serotonin-induced pulmonary vasoconstriction and the enhanced vascular reactivity in chronic hypoxic pulmonary hypertension". American Journal of Physiology. Cell Physiology 305(7): C690-C692, 2013